New and emerging therapies for paediatric atopic dermatitis (Q92572613)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

30 April 2020

title

New and emerging therapies for paediatric atopic dermatitis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

30 April 2020

1 reference

Paras P Vakharia

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

30 April 2020

Jonathan I Silverberg

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

30 April 2020

publication date

20 March 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

The Lancet Child & Adolescent Health

30 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

30 April 2020

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

30 April 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

30 April 2020

page(s)

343-353

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

Epidemiology of childhood atopic dermatitis.

30 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

A systematic review and meta-analysis of the regional and age-related differences of atopic dermatitis clinical characteristics

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

New insights into atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Genetic and epigenetic studies of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Filaggrin loss-of-function mutations are not associated with atopic dermatitis that develops in late childhood or adulthood

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Environmental risk factors and their role in the management of atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Cytokines and T cells in atopic dermatitis.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Janus kinase inhibitors in dermatology: A systematic review

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Elevated leukocyte cyclic AMP—phosphodiesterase in atopic disease: a possible mechanism for cyclic AMP—agonist hyporesponsiveness

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Calcitonin gene-related peptide inhibits lipopolysaccharide-induced interleukin-12 release from mouse peritoneal macrophages, mediated by the cAMP pathway

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Guidelines for treatment of atopic eczema (atopic dermatitis) part I.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Emollients and moisturisers for eczema: abridged Cochrane systematic review including GRADE assessments.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy and Safety of Tacrolimus versus Pimecrolimus for the Treatment of Atopic Dermatitis in Children: A Network Meta-Analysis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Update on the management of chronic eczema: new approaches and emerging treatment options

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Special Considerations for Therapy of Pediatric Atopic Dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

The Role and Diagnosis of Allergic Contact Dermatitis in Patients with Atopic Dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clin

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Dupilumab in persistent asthma with elevated eosinophil levels

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Interleukin-13 in Asthma and Other Eosinophilic Disorders.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Progressive multifocal leukoencephalopathy associated with ruxolitinib

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild to moderate atopic dermatitis (AD): A phase-II randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Effect of topical phosphodiesterase 4 inhibitor E6005 on Japanese children with atopic dermatitis: Results from a randomized, vehicle-controlled exploratory trial

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Safety and efficacy of topical E6005, a phosphodiesterase 4 inhibitor, in Japanese adult patients with atopic dermatitis: results of a randomized, vehicle-controlled, multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

IgE, mast cells, and eosinophils in atopic dermatitis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Omalizumab for atopic dermatitis: case series and a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Tapinarof Is a Natural AhR Agonist that Resolves Skin Inflammation in Mice and Humans

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

AhR sensing of bacterial pigments regulates antibacterial defence.

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Resolving Inflammation by Targeting an Ancient Innate Immune Sensor with a Bacterial Metabolite

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Efficacy and safety of topical WBI-1001 in patients with mild to severe atopic dermatitis: results from a 12-week, multicentre, randomized, placebo-controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

Neuroimmunological mechanism of pruritus in atopic dermatitis focused on the role of serotonin

1 reference

https://api.crossref.org/works/10.1016/S2352-4642(19)30030-6

7 January 2021

10.1016/S2352-4642(19)30030-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30904349 AND SRC:MED&resulttype=core&format=json

30 April 2020

1 reference